Palisade Bio Inc. Stock
Palisade Bio Inc. Stock
Based on 2 Buy predictions and 1 Sell predictions the sentiment towards Palisade Bio Inc. is rather balanced.
With a target price of 11 € there is potential for a 3123.92% increase which would mean more than doubling the current price of 0.34 € for Palisade Bio Inc..
Our community identified positive and negative aspects for Palisade Bio Inc. stock for the coming years. 1 users see the criterium "Company culture" as a plus for the Palisade Bio Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Palisade Bio Inc. in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Palisade Bio Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Palisade Bio Inc. | - | - | - | - | - | - | - |
Rockwell Medical Inc. | 1.620% | 3.561% | -4.362% | -26.923% | -20.034% | -85.152% | -96.854% |
Avid Bioservices Inc | 3.170% | 9.244% | 1.563% | -61.310% | 6.557% | -63.068% | 49.683% |
Gritstone Oncology Inc | 7.500% | 11.232% | -68.154% | -65.271% | -58.692% | -90.436% | - |
Comments
Palisade Bio, Inc. (NASDAQ: PALI) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $22.50 price target on the stock.
Show more
Ratings data for PALI provided by MarketBeat
Palisade Bio, Inc. (NASDAQ: PALI) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. They now have a $1.50 price target on the stock.
Show more
Ratings data for PALI provided by MarketBeat
Palisade Bio, Inc. (NASDAQ: PALI) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating.
Show more
Ratings data for PALI provided by MarketBeat